Immunomonitoring measures in relapsing-remitting multiple sclerosis.
D000293:Adolescent; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D016207:Cytokines / Q000276:immunology*; D005110:Extracellular Space / Q000187:drug effects / Q000276:immunology; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000276:immunology*; D012737:Sex Factors; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology; D014763:Viral Matrix Proteins / Q000627:therapeutic use
D016207:Cytokines; C031540:M-protein, influenza virus; D014763:Viral Matrix Proteins